vs
Side-by-side financial comparison of Pacira BioSciences, Inc. (PCRX) and Ribbon Communications Inc. (RBBN). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $162.6M, roughly 1.1× Ribbon Communications Inc.). Ribbon Communications Inc. runs the higher net margin — 54.8% vs 1.6%, a 53.1% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs -10.3%). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (-0.2% CAGR vs -8.1%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
Ribbon Communications Inc. is a public company that makes software, IP and optical networking solutions for service providers, enterprises and critical infrastructure sectors. The company was formed in 2017, following the merger of Genband and Sonus Networks and is headquartered in Plano, Texas.
PCRX vs RBBN — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $177.4M | $162.6M |
| Net Profit | $2.9M | $89.1M |
| Gross Margin | — | 42.9% |
| Operating Margin | 3.9% | 37.6% |
| Net Margin | 1.6% | 54.8% |
| Revenue YoY | 5.0% | -10.3% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.07 | $0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $177.4M | $162.6M | ||
| Q4 25 | $196.9M | $227.3M | ||
| Q3 25 | $179.5M | $215.4M | ||
| Q2 25 | $181.1M | $220.6M | ||
| Q1 25 | $168.9M | $181.3M | ||
| Q4 24 | $187.3M | $251.4M | ||
| Q3 24 | $168.6M | $210.2M | ||
| Q2 24 | $178.0M | $192.6M |
| Q1 26 | $2.9M | $89.1M | ||
| Q4 25 | — | — | ||
| Q3 25 | $5.4M | $-12.1M | ||
| Q2 25 | $-4.8M | $-11.1M | ||
| Q1 25 | $4.8M | $-26.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-143.5M | $-13.4M | ||
| Q2 24 | $18.9M | $-16.8M |
| Q1 26 | — | 42.9% | ||
| Q4 25 | 79.5% | 53.3% | ||
| Q3 25 | 80.9% | 50.1% | ||
| Q2 25 | 77.4% | 49.6% | ||
| Q1 25 | 79.7% | 45.4% | ||
| Q4 24 | 78.7% | 55.7% | ||
| Q3 24 | 76.9% | 52.1% | ||
| Q2 24 | 75.1% | 50.8% |
| Q1 26 | 3.9% | 37.6% | ||
| Q4 25 | 1.2% | 4.1% | ||
| Q3 25 | 3.5% | 1.3% | ||
| Q2 25 | 4.7% | 1.9% | ||
| Q1 25 | 1.2% | -10.8% | ||
| Q4 24 | 13.2% | 13.2% | ||
| Q3 24 | -82.8% | -0.4% | ||
| Q2 24 | 15.9% | -1.0% |
| Q1 26 | 1.6% | 54.8% | ||
| Q4 25 | — | — | ||
| Q3 25 | 3.0% | -5.6% | ||
| Q2 25 | -2.7% | -5.0% | ||
| Q1 25 | 2.8% | -14.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | -85.1% | -6.4% | ||
| Q2 24 | 10.6% | -8.7% |
| Q1 26 | $0.07 | $0.50 | ||
| Q4 25 | $0.05 | $0.50 | ||
| Q3 25 | $0.12 | $-0.07 | ||
| Q2 25 | $-0.11 | $-0.06 | ||
| Q1 25 | $0.10 | $-0.15 | ||
| Q4 24 | $0.38 | $0.05 | ||
| Q3 24 | $-3.11 | $-0.08 | ||
| Q2 24 | $0.39 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $144.3M | $67.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $653.9M | $419.1M |
| Total Assets | $1.2B | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $144.3M | $67.6M | ||
| Q4 25 | $238.4M | $96.4M | ||
| Q3 25 | $246.3M | $74.8M | ||
| Q2 25 | $445.9M | $60.5M | ||
| Q1 25 | $493.6M | $71.2M | ||
| Q4 24 | $484.6M | $87.8M | ||
| Q3 24 | $453.8M | $37.2M | ||
| Q2 24 | $404.2M | $64.6M |
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | $342.1M | ||
| Q3 25 | $376.7M | $344.3M | ||
| Q2 25 | $580.5M | $346.5M | ||
| Q1 25 | $583.4M | $347.4M | ||
| Q4 24 | $585.3M | $348.3M | ||
| Q3 24 | — | $349.1M | ||
| Q2 24 | — | $350.0M |
| Q1 26 | $653.9M | $419.1M | ||
| Q4 25 | $693.1M | $449.0M | ||
| Q3 25 | $727.2M | $360.1M | ||
| Q2 25 | $757.8M | $370.4M | ||
| Q1 25 | $798.5M | $381.8M | ||
| Q4 24 | $778.3M | $404.6M | ||
| Q3 24 | $749.6M | $395.5M | ||
| Q2 24 | $879.3M | $405.0M |
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.3B | $1.2B | ||
| Q3 25 | $1.3B | $1.1B | ||
| Q2 25 | $1.5B | $1.1B | ||
| Q1 25 | $1.6B | $1.1B | ||
| Q4 24 | $1.6B | $1.2B | ||
| Q3 24 | $1.5B | $1.1B | ||
| Q2 24 | $1.6B | $1.1B |
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | 0.76× | ||
| Q3 25 | 0.52× | 0.96× | ||
| Q2 25 | 0.77× | 0.94× | ||
| Q1 25 | 0.73× | 0.91× | ||
| Q4 24 | 0.75× | 0.86× | ||
| Q3 24 | — | 0.88× | ||
| Q2 24 | — | 0.86× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
RBBN
| Service | $94.5M | 58% |
| Product | $68.1M | 42% |
